2026 Semi-Annual Report Summary
Jiangxi Tianxin Pharmaceutical Co., Ltd. 2026 Semi-annual Report Summary Company Code: 603235 Company Abbreviation: Tianxin Pharmaceutical
Jiangxi Tianxin Pharmaceutical Co., Ltd.
2026 Interim Report Summary
Summary of the 2026 Semi-Annual Report of Jiangxi Tianxin Pharmaceutical Co., Ltd.
Section 1 Important Tips
1.1 The summary of this semi-annual report comes from the full text of the semi-annual report. In order to fully understand the company's operating results, financial status and future development plans, investors should go to the http://www.sse.com.cn website to read the full text of the semi-annual report carefully. 1.2 The company’s board of directors, directors and senior managers guarantee the authenticity, accuracy and completeness of the contents of the semi-annual report and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability. 1.3 All directors of the company shall attend the board meeting.
1.4 This semi-annual report has not been audited.
1.5 The profit distribution plan for the reporting period or the plan for converting public reserve funds into share capital passed by the board of directors
None
Summary of the 2026 Semi-Annual Report of Jiangxi Tianxin Pharmaceutical Co., Ltd.
Section 2 Basic Information of the Company
2.1 Company Profile
Company Stock Profile
Stock type Stock listing exchange Stock abbreviation Stock code Stock abbreviation before change A shares Shanghai Stock Exchange Tianxin Pharmaceutical 603235 -
Contact and Contact Information Secretary of the Board Securities Affairs Representative
Name Dong Yi Lin Li
Phone: 0798-6709288 0798-6709288
Office address Leping Industrial Park, Jingdezhen City, Jiangxi Province Leping Industrial Park, Jingdezhen City, Jiangxi Province E-mail [email protected] [email protected]
2.2 Main financial data
Unit: Yuan Currency: RMB The end of the reporting period compared with the end of the previous year The end of the reporting period The end of the previous year
Increase or decrease (%) in total assets at the end of the period 6,441,509,387.88 6,189,720,256.37 4.07 Net assets attributable to shareholders of listed companies 4,996,498,254.40 4,916,517,109.39 1.63 This reporting period is compared with the same period of the previous year.
Period increase or decrease (%) operating income 1,309,382,533.34 1,122,350,298.53 16.66Total profit 380,435,214.86 424,589,540.26 -10.40Net profit attributable to shareholders of listed companies 319,324,799.01 356,013,549.30 -10.31 Deductions attributable to shareholders of listed companies are not
297,969,899.05 336,278,264.05 -11.39 Net profit from recurring gains and losses
Net cash flow generated from operating activities 383,577,179.14 341,997,699.35 12.16 Weighted average return on equity (%) 6.34 7.42 Decrease by 1.08 percentage points Basic earnings per share (yuan/share) 0.73 0.82 -10.98 Diluted earnings per share (yuan/share) 0.73 0.82 -10.98
2.3 List of shareholdings of the top 10 shareholders
Unit: Share Total number of shareholders (households) as of the end of the reporting period 11,435 Total number of preference shareholders (households) whose voting rights have been restored as of the end of the reporting period -
Shareholding status of the top 10 shareholders
Summary of the 2026 Semi-Annual Report of Jiangxi Tianxin Pharmaceutical Co., Ltd.
Limited holding
Shareholding ratio Shareholding Pledged, marked or frozen name of shareholder Nature of shareholder Conditions for sale
Example (%) Number of shares of quantity
Number of shares
Xu Jiangnan Domestic natural person 46.51 203,603,970 - N/A -Xu Jing Domestic natural person 13.50 59,110,830 - N/A -Wang Guangtian Domestic natural person 12.98 56,803,200 - N/A -Qiu Qinyong Domestic natural person 8.11 35,502,000 - N/A -Tiantai County Houding Investment Management
Others 5.48 24,000,000 - None - Partnership (limited partnership)
Chen Weimin Domestic natural person 2.51 10,980,000 - N/A - Zhang Qimei Domestic natural person 0.66 2,886,491 - N/A - Qiao Meng Domestic natural person 0.52 2,259,842 - N/A - Cheng Wenhua Domestic natural person 0.47 2,060,800 - N/A - Tiantai County Housheng Investment Management
Others 0.46 2,000,000 - None -Partnership (limited partnership)
Tiantai County Houtai Investment Management
Others 0.46 2,000,000 - None - Partnership (limited partnership)
Xu Jiangnan is the controlling shareholder and actual controller of the company, and Xu Jing is his daughter. Houding Investment, Housheng Investment, and Houtai Investment are all company employee stockholding platforms controlled by Xu Jiangnan. Xu Jiangnan, Xu Jing and the above three shareholding platforms are persons acting in concert.
Zhang Qimei is the spouse of Qiu Qinyong, and they constitute persons acting in concert. Explanation of the above-mentioned shareholders’ related relationships or concerted actions
Xu Jiangnan, Xu Jing, Wang Guangtian, Qiu Qinyong, and Chen Weimin all indirectly hold partnership shares in Houding Investment, Housheng Investment, and Houtai Investment through Huihong Investment.
The company is not aware of any related relationship or concerted behavior among the other shareholders mentioned above.
moving situation.
Preference shareholders whose voting rights have been restored and the number of shares they hold
Not applicable
Description
Note: Among the top ten shareholders, Tiantai County Housheng Investment Management Partnership (Limited Partnership) and Tiantai County Houtai Investment Management Partnership (Limited Partnership) are tied for tenth.
2.4 Total number of preference shareholders and top 10 preference shareholders as of the end of the reporting period
□Applicable √Not applicable
2.5 Changes in controlling shareholders or actual controllers
□Applicable √Not applicable
2.6 Status of bonds existing on the date of approval of the semi-annual report
□Applicable √Not applicable
Summary of the 2026 Semi-Annual Report of Jiangxi Tianxin Pharmaceutical Co., Ltd.
Section 3 Important Matters
The company shall, in accordance with the principle of materiality, explain the major changes in the company's operating conditions during the reporting period, as well as the matters that occurred during the reporting period that have a significant impact on the company's operating conditions and are expected to have a significant impact in the future.
□Applicable √Not applicable